An interventional study of Shared decision-making tool in Atrial Fibrillation and Patient Engagement, sponsored by Columbia University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Columbia University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 431st largest by enrollment of the 679 interventional ones that give a count, is one of 54 that started in 2024, is one of 405 with no phase, and was the 733rd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 40+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 54 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
Columbia University has 3 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
75 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 75 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-group feasibility study evaluating decision aid visualizations which display common post-ablation symptom patterns as a tool for shared decision-making. The specific aim of the clinical trial is to evaluate the feasibility of putting the visualizations into clinical practice (n=75). The hypothesis is that patients will report low decisional conflict and decision regret and high satisfaction with their decision about whether to undergo an ablation or not.
Atrial fibrillation (AF) is the most common heart rhythm disorder, and nearly 90% of patients experience symptoms such as shortness of breath that directly impair their health-related quality of life (HRQoL). Catheter ablation is a minimally invasive, surgical procedure that is routinely performed to treat AF and associated symptoms with the goal of improving HRQOL, but also carries potentially serious risks. Shared decision-making (SDM), in which treatment decisions are aligned based on high quality evidence and patient values and goals of care, is a widely encouraged practice for navigating complex healthcare decisions such as these. However, SDM around rhythm and symptom management does not routinely occur due to a lack of detailed evidence about symptom improvement post-ablation, and a lack of decision aids to communicate evidence to patients. The overarching goal of this award is to create an interactive patient decision aid composed of established evidence from clinical trials together with novel "real world" evidence about symptom improvement post ablation mined from electronic health records (EHRs).
The investigators propose to use "real-world evidence" drawn from electronic health records (EHRs) to characterize post-ablation symptom patterns, and display them in decision-aid visualizations to support shared decision-making (SDM). In this project, the investigators will first use natural language processing (NLP) and machine learning (ML) to extract and analyze symptom data from narrative notes in EHRs. The investigators will also employ a rigorous, user-centered design protocol created during the Principal Investigator's post-doctoral work to develop decision-aid visualizations. In the clinical trial, the investigators will evaluate the feasibility of implementing these interactive decision-aid visualizations in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will view a shared decision-making tool while they are undergoing consultation to have an atrial fibrillation ablation.
Other: Shared decision-making tool
Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
Baseline Decisional Conflict Assessed Using the Decisional Conflict Scale
Conflict about the decision to undergo atrial fibrillation will be assessed using the Decisional Conflict Scale on a scale of 0 (no decisional conflict) to 100 (extremely high decisional conflict).
Time frame: Baseline
Two Week Decisional Conflict Assessed Using the Decisional Conflict Scale
Conflict about the decision to undergo atrial fibrillation will be assessed using the Decisional Conflict Scale on a scale of 0 (no decisional conflict) to 100 (extremely high decisional conflict).
Time frame: 2 weeks
Baseline Decision Self-Efficacy Score Assessed Using the Decision Self-Efficacy Scale
The Decision Self-Efficacy Scale ranges from 0-100; higher indicates more self-efficacy.
Time frame: Baseline
Two Week Decision Self-efficacy Assessed Using the Decisional Self-Efficacy Scale
The Decision Self-Efficacy Scale ranges from 0-100; higher indicates more self-efficacy.
Time frame: 2 weeks
Post-ablation Symptom Burden Assessed Using the Atrial Fibrillation Severity Scale (AFSS)
The severity of atrial fibrillation symptoms after an ablation will be assessed using the AFSS on a scale of 0 (no symptom burden) to 35 (extremely high symptom burden).
Time frame: 12 weeks
Post-ablation Health-related Quality of Life Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire
Health-related quality of life after an ablation will be assessed using the AFEQT on a scale of 0 (complete disability) to 100 (high quality of life).
Time frame: 12 weeks
| Milestone | Pilot Cohort |
|---|---|
| Started | 75 |
| Completed | 58 |
| Not completed | 17 |
| Withdrew: Lost to follow-up | 17 |
Conflict about the decision to undergo atrial fibrillation will be assessed using the Decisional Conflict Scale on a scale of 0 (no decisional conflict) to 100 (extremely high decisional conflict).
| Score | Intervention Arm |
|---|---|
| Baseline Decisional Conflict Assessed Using the Decisional Conflict Scale | 25.1 ± 18.0 |
Conflict about the decision to undergo atrial fibrillation will be assessed using the Decisional Conflict Scale on a scale of 0 (no decisional conflict) to 100 (extremely high decisional conflict).
| Score | Intervention Arm |
|---|---|
| Two Week Decisional Conflict Assessed Using the Decisional Conflict Scale | 30.3 ± 25.5 |
The Decision Self-Efficacy Scale ranges from 0-100; higher indicates more self-efficacy.
| Score | Pilot Cohort |
|---|---|
| Baseline Decision Self-Efficacy Score Assessed Using the Decision Self-Efficacy Scale | 40.7 ± 11.3 |
The severity of atrial fibrillation symptoms after an ablation will be assessed using the AFSS on a scale of 0 (no symptom burden) to 35 (extremely high symptom burden).
| Score | Pilot Cohort |
|---|---|
| Post-ablation Symptom Burden Assessed Using the Atrial Fibrillation Severity Scale (AFSS) | 4.60 ± 5.27 |
Health-related quality of life after an ablation will be assessed using the AFEQT on a scale of 0 (complete disability) to 100 (high quality of life).
| Score | Pilot Cohort |
|---|---|
| Post-ablation Health-related Quality of Life Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire | 80.86 ± 15.61 |
The Decision Self-Efficacy Scale ranges from 0-100; higher indicates more self-efficacy.
| Score | Pilot Cohort |
|---|---|
| Two Week Decision Self-efficacy Assessed Using the Decisional Self-Efficacy Scale | 38.9 ± 9.8 |
Collected over From enrollment up to 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pilot Cohort | 0/75 (0%) | 0/75 (0%) | 0/75 (0%) |
| Age, Continuous(Years) | Pilot Cohort |
|---|---|
| Mean | 67.1 ± 12.4 |
| Sex: Female, Male(Participants) | Pilot Cohort |
|---|---|
| Female | 25 |
| Male | 50 |
| Race (NIH/OMB)(Participants) | Pilot Cohort |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 62 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
| Ethnicity (NIH/OMB)(Participants) | Pilot Cohort |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 66 |
| Unknown or Not Reported | 7 |
| Decisional Conflict Score(Score) | Pilot Cohort |
|---|---|
| Mean | 25.1 ± 18.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) will be available to other researchers upon reasonable request after Data Use Agreements have been executed.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 3 years and ending 5 years following publication.
Access criteria: Researchers who provide a methodologically sound proposal and have completed Data Use Agreements.
Ran from Mar 2024 to primary completion in Jun 2025, 14 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 14 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.